RT Journal Article
SR Electronic
T1 Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20162917
DO 10.1101/2020.07.29.20162917
A1 Michael J. Joyner
A1 Stephen A. Klassen
A1 Jonathon W. Senefeld
A1 Patrick W. Johnson
A1 Rickey E. Carter
A1 Chad C. Wiggins
A1 Shmuel Shoham
A1 Brenda J. Grossman
A1 Jeffrey P. Henderson
A1 James M. Musser
A1 Eric Salazar
A1 William R. Hartman
A1 Nicole M. Bouvier
A1 Sean T. H. Liu
A1 Liise-anne Pirofski
A1 Sarah E. Baker
A1 Noud van Helmond
A1 R. Scott Wright
A1 DeLisa Fairweather
A1 Katelyn A. Bruno
A1 Nigel S. Paneth
A1 Arturo Casadevall
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20162917.abstract
AB To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from randomized clinical trials, matched control, and case-series studies. Fixed-effects analyses demontrated that hospitalized COVID-19 patients transfused with convalescent plasma exhibited a ∼57% reduction in mortality rate (13%) compared to matched-patients receiving standard treatments (25%; OR: 0.43, P < 0.001). These data provide evidence favouring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures accessed public information and did not require ethical review as determined by the Mayo Clinic Institutional Review Board in accordance with the Code of Federal Regulations, 45 CFR 46.102, and the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll procedures accessed public information as sourced in the main text.